Next Article in Journal
Using Machine Learning Techniques for Asserting Cellular Damage Induced by High-LET Particle Radiation
Previous Article in Journal
Selective Pressure-Free Treatments for COVID-19
Article

Biodistribution and Radiation Dosimetric Analysis of [68Ga]Ga-RM2: A Potent GRPR Antagonist in Prostate Carcinoma Patients

Department of Nuclear Medicine, University Medical Center Bonn, 53127 Bonn, Germany
*
Author to whom correspondence should be addressed.
Both authors contributed in equal to the manuscript.
Radiation 2021, 1(1), 33-44; https://doi.org/10.3390/radiation1010004
Received: 20 November 2020 / Revised: 21 December 2020 / Accepted: 25 December 2020 / Published: 30 December 2020
(This article belongs to the Section Radiation in Medical Imaging)
[68Ga]Ga-RM2 is a promising innovative positron emission tomography (PET) tracer for patients with primary or metastatic prostate carcinoma. This study aims to analyze the biodistribution and radiation dosimetry of [68Ga]Ga-RM2 in five prostate cancer patients. The percentages of injected activity in the source organs and blood samples were determined. Bone marrow residence time was calculated using an indirect blood-based method. OLINDA/EXM version 2.0 (Hermes Medical Solutions, Stockholm, Sweden) was used to determine residence times, organ absorbed and effective doses. Physiological uptake was seen in kidneys, urinary bladder, pancreas, stomach, spleen and liver. Blood clearance was fast and followed by rapid clearance of activity from kidneys resulting in high activity concentrations in the urinary bladder. The urinary bladder wall was the most irradiated organ with highest mean organ absorbed dose (0.470 mSv/MBq) followed by pancreas (0.124 mSv/MBq), stomach wall (0.063 mSv/MBq), kidneys (0.049 mSv/MBq) and red marrow (0.010 mSv/MBq). The effective dose was found to be 0.038 mSv/MBq. Organ absorbed doses were found to be comparable to other gallium-68 labelled GRPR antagonists and lower than [68Ga]Ga-PSMA with the exception of the urinary bladder, pancreas and stomach wall. Remarkable interindividual differences were observed for the organ absorbed doses. Therefore, [68Ga]Ga-RM2 is a safe diagnostic agent with a significantly lower kidney dose but higher pancreas and urinary bladder doses as compared to [68Ga]Ga-PSMA. View Full-Text
Keywords: prostate cancer; positron emission tomography; gastrin releasing peptide receptor; organ dosimetry; biodistribution prostate cancer; positron emission tomography; gastrin releasing peptide receptor; organ dosimetry; biodistribution
Show Figures

Figure 1

MDPI and ACS Style

Haendeler, M.; Khawar, A.; Ahmadzadehfar, H.; Kürpig, S.; Meisenheimer, M.; Essler, M.; Gaertner, F.C.; Bundschuh, R.A. Biodistribution and Radiation Dosimetric Analysis of [68Ga]Ga-RM2: A Potent GRPR Antagonist in Prostate Carcinoma Patients. Radiation 2021, 1, 33-44. https://doi.org/10.3390/radiation1010004

AMA Style

Haendeler M, Khawar A, Ahmadzadehfar H, Kürpig S, Meisenheimer M, Essler M, Gaertner FC, Bundschuh RA. Biodistribution and Radiation Dosimetric Analysis of [68Ga]Ga-RM2: A Potent GRPR Antagonist in Prostate Carcinoma Patients. Radiation. 2021; 1(1):33-44. https://doi.org/10.3390/radiation1010004

Chicago/Turabian Style

Haendeler, Matthias, Ambreen Khawar, Hojjat Ahmadzadehfar, Stefan Kürpig, Michael Meisenheimer, Markus Essler, Florian C. Gaertner, and Ralph A. Bundschuh 2021. "Biodistribution and Radiation Dosimetric Analysis of [68Ga]Ga-RM2: A Potent GRPR Antagonist in Prostate Carcinoma Patients" Radiation 1, no. 1: 33-44. https://doi.org/10.3390/radiation1010004

Find Other Styles

Article Access Map by Country/Region

1
Back to TopTop